Post-vaccination Adverse Reactions After Receiving the Pfizer-BioNTech Coronavirus Disease 2019 Vaccines Among Healthcare Workers in Sapporo, Japan.

Background/objective Although a third dose of the coronavirus disease 2019 vaccine was initiated, the reports of the post-vaccination adverse reactions after dose three from Japan were limited. We aimed to report on post-vaccination adverse reactions to the third dose of the vaccine among healthcare workers and compare the results with those after the first two doses of vaccine at a tertiary medical center in Japan. Materials and methods After each vaccine (Pfizer-BioNTech) administration, healthcare workers answered a Web-based questionnaire for two consecutive days regarding local and systemic adverse reactions and anaphylaxis reactions. Information about those who took antipyretics and analgesics was also collected. Data were collected using Microsoft Forms (Microsoft, Redmond, WA, USA), a web-based questionnaire software. We compared the proportions of post-vaccination adverse reactions among the three doses of vaccine using the chi-squared test. Results A total of 1,990 employees received the first dose in March 2021, 1,988 employees received the second dose in April 2021, and 1,748 employees received the third dose between December 2021 and January 2022. The median age was 32 years and 21% were men. Local and systemic adverse reactions were greater after dose three than those with the primary series, except for nausea and vomiting. Injected site pain, fatigue, and headache were the three most commonly reported adverse reactions throughout the three sessions. A total of four employees developed anaphylaxis reactions. Additionally, 944 and 1,016 employees reported taking antipyretics and analgesics after doses two and three. Conclusions The coronavirus 2019 booster vaccine was safe and well-tolerated. Clinicians should encourage the public to receive the coronavirus 2019 vaccine series.

A single-center comparative analysis of outpatients with and without COVID-19 in Sapporo, Japan.

This study aimed to investigate the demographic, clinical, and epidemiological statistics of Japanese patients attending a designated outpatient clinic for COVID-19 in Sapporo, Japan, and contrast the clinical and epidemiological features between those with and without mild COVID-19. A total of 27 (8.6%) of 315 patients were diagnosed with COVID-19. They had higher proportions of myalgia, direct contact with a confirmed COVID-19 patient, and attendance of social gatherings in close confines. We believe that our study makes a significant contribution to the literature because it provides a clinical picture of mild COVID-19 in the Japanese population, which has not been studied extensively. It can also assist in optimizing the local preventive measures to reduce the transmission of COVID-19.

Minimally invasive repair of right-sided blunt traumatic diaphragmatic injury.

Right-sided blunt traumatic diaphragmatic injury (TDI) is a rare injury that is rarely repaired by the minimally invasive approach in the acute setting. Laparoscopic repair of right-sided TDI is challenging because the liver often obstructs access to the injury site. Herein, we report a case wherein acute right-sided blunt TDI was successfully repaired using a combined laparoscopic and thoracoscopic approach. A 30-year-old man presented with shortness of breath after falling on his back while jumping on a snowboard. CT revealed a right-sided TDI. As the patient was haemodynamically stable, laparoscopic repair was planned. Laparoscopy revealed a right-sided diaphragmatic rupture. As the posterior portion was covered by the liver and difficult to access, we added trocars in the chest cavity and closed the diaphragmatic defect with a thoracic approach. A combined laparoscopic and thoracoscopic approach can repair right-sided diaphragmatic injury by a minimally invasive approach even in the acute setting.

Pathological complete response of locally advanced colon cancer after preoperative radiotherapy: a case report and narrative review of the literature.

BACKGROUND: The oncological effectiveness of preoperative radiotherapy for locally advanced colon cancer is unclear. We report a case of pathological complete response in a patient with locally advanced ascending colon cancer after preoperative radiotherapy following failure of chemotherapy. CASE PRESENTATION: A 65-year-old Japanese woman presented with malaise and hematochezia. A computed tomography (CT) revealed a tumor in the ascending colon which seemed to infiltrate the adjacent structures. She was diagnosed with locally advanced ascending colon cancer stages T4b, N2a, M0, and IIIC. We selected modified FOLFOX6 with panitumumab as neoadjuvant chemotherapy. However, we discontinued the chemotherapy after the 8th cycle because of disease progression and severe adverse effects. The patient then underwent radiotherapy of 60 Gy in 30 fractions, resulting in significant tumor size reduction. One month after the radiotherapy, we performed a right hemicolectomy with multivisceral resection without complications. Histopathologically, we found no residual cancer cells in the resected specimen. The patient remains alive and has not required additional therapies for 24 months, as there are no signs of recurrence. CONCLUSIONS: The present case suggests that preoperative radiotherapy might be an effective treatment options for locally advanced colon cancer.

[Sarcomatoid carcinoma of the liver: a case report and review of the literature].

A 66-year-old woman presented to our outpatient clinic with abdominal discomfort in April, 2008. Ultrasound revealed a hypo-echoic 10cm mass in the right hepatic lobe but no indication of chronic liver disease, with similar results in her history, on physical exam, and imaging. Serum testing did not identify any systemic disease. The mass was suspected to be intrahepatic cholangiocarcinoma and right hepatic lobectomy was performed. Histologic examination of the specimen revealed numerous spindle cells, and immunostaining confirmed a definitive diagnosis of sarcomatoid carcinoma of the liver. On subsequent review of the case, an abdominal CT performed 2.5 years earlier for unrelated symptoms had shown a 1cm faint low density area in the same location as the mass. The doubling time of this tumor was about 95 days.

Long-term survival after curative left hepatectomy for mucin-producing cholangiocarcinoma: report of a case.

Cholangiocarcinomas are rarely mucinproducing. We report a case of mucin-producing cholangiocarcinoma successfully treated by curative left hepatectomy, resulting in long-term survival, with no evidence of tumor recurrence 111 months after resection. Immunohistochemical studies revealed a pattern of MUC-1 negativity and MUC-2 positivity, suggesting low malignant potential.

Embolization of the replaced common hepatic artery before surgery for pancreatic head cancer: report of a case.

We report the case of a patient with pancreatic head cancer, whose replaced common hepatic artery (RCHA) arose from the superior mesenteric artery (SMA). We performed preoperative embolization of the RCHA, after which the liver blood flow was well maintained by the left gastric artery. The patient underwent a radical operation involving en bloc resection of the RCHA without any serious complications.

Role of hepatectomy in the treatment of hilar bile duct carcinoma.

PURPOSE: To clarify the role of hepatic resection in the surgical treatment of hilar bile duct carcinoma. METHODS: Between 1980 and 1997, 68 patients underwent surgery for hilar bile duct carcinoma. The patients were divided into a hepatectomy group ( n = 40) and a nonhepatectomized group ( n = 28) depending on whether they underwent resection of the bile duct confluence in combination with hepatectomy, or alone, respectively. Background data, operative morbidity and mortality, and survival were retrospectively compared between the two groups. RESULTS: There were no significant differences in morbidity and mortality, or in postoperative survival between the two groups (the 5-year survival rates being 20.6% in the hepatectomized group and 7.1% in the nonhepatectomized group; P = 0.0806). However, patients who underwent curative resection had significantly better postoperative survival than those who underwent noncurative resection ( P = 0.048). Hepatectomy provided a significantly better cancer-free margin than bile duct resection alone ( P = 0.0296). CONCLUSIONS: Although a countermeasure must be taken to decrease mortality, the introduction of hepatectomy with bile duct resection would provide a better cancer-free surgical margin than bile duct resection alone for hilar bile duct carcinoma. Curative resection contributed to long-term survival in this series.